Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: Data from the avoid delivering therapies for nonsustained arrhythmias in ICD patients III (ADVANCE III) trial

Circulation

Volumn 130, Issue 4, 2014, Pages 308-314

  Kloppe, Axel ^a   Proclemer, Alessandro ^b   Arenal, Angel ^c   Lunati, Maurizio ^d   Martìnez Ferrer, José Bautista ^e   Hersi, Ahmad ^f   Gulaj, Marcin ^g   Wijffels, Maurits C E F ^h   Santi, Elisabetta ⁱ   Manotta, Laura ^j   Mangoni, Lorenza ⁱ   Gasparini, Maurizio ^k  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e HOSPITAL TXAGORRITXU   (Spain)

^f KING SAUD UNIVERSITY   (Saudi Arabia)

^g MSWiA Specialized Hospital   (Poland)

^h ST ANTONIUS HOSPITAL   (Netherlands)

ⁱ Medtronic Italia   (Italy)

^j Medtronic Clinical Research Institute   (Italy)

^k HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

more..

Author keywords

arrhythmia; cardiac; electrical; implantable cardioverter defibrillators; secondary prevention; shock; stimulators

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CLINICAL TRIAL; FEMALE; HEART EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION;

ARRHYTHMIA; IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; SECONDARY PREVENTION; STIMULATORS, ELECTRICAL, CARDIAC, SHOCK;

AGED; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; EQUIPMENT FAILURE; FEMALE; HEART RATE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PRIMARY PREVENTION; RECURRENCE; SECONDARY PREVENTION; SINGLE-BLIND METHOD; STROKE VOLUME; SYNCOPE; TACHYCARDIA, VENTRICULAR; TIME FACTORS; VENTRICULAR FIBRILLATION;

EID: 84904767786     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.009468     Document Type: Article

References (17)

1. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.
2. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-754.
3. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M; for the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933-1940.
4. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
5. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillator in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576-1583.
6. Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol. 2004;15:1002-1009.
7. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, Schuger C, Steinberg JS, Higgins SL, Wilber DJ, Klein H, Andrews ML, Hall WJ, Moss AJ; MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008;51:1357-1365.
8. Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, Hersi A, Gulaj M, Wijfels MC, Santi E, Manotta L, Arenal A. Effect of long-detection interval vs standard-detection interval for implantable cardioverter- defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013;309:1903-1911.
9. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, Estes NA 3rd, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, Olshansky B, Shoda M, Wilber D, Zareba W; MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367:2275-2283.
10. Saeed M, Hanna I, Robotis D, Styperek R, Polosajian L, Khan A, Alonso J, Nabutovsky Y, Neason C. Programming Implantable Cardioverter- Defibrillators in Patients With Primary Prevention Indication to Prolong Time to First Shock: results from the PROVIDE study. J Cardiovasc Electrophysiol. 2013;25:52-59.
11. Schwab JO, Gasparini M, Lunati M, Proclemer A, Kaup B, Santi E, Ligorio G, Klersy C, DE Sousa J, Okreglicki A, Arenal A, Wijffels M, Lemke B. Avoid Delivering Therapies for Nonsustained Fast Ventricular Tachyarrhythmia in Patients With Implantable Cardioverter/Defibrillator: the ADVANCE III Trial. J Cardiovasc Electrophysiol. 2009;20:663-666.
12. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, Khalighi K, Machado C, Rubenstein DS, Volosin KJ; PainFREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter defibrillators: PainFREE Rx II trial results. Circulation. 2004;104:796-801.
13. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Fishbein DP, Packer DL, Mark DB, Lee KL, Bardy GH. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009-1017.
14. Tereshchenko LG, Faddis MN, Fetics BJ, Zelik KE, Efimov IR, Berger RD. Transient local injury current in right ventricular electrogram after implantable cardioverter-defibrillator shock predicts heart failure progression. J Am Coll Cardiol. 2009;54:822-828.
15. Gasparini M, Menozzi C, Proclemer A, Landolina M, Iacopino S, Carboni A, Lombardo E, Regoli F, Biffi M, Burrone V, Denaro A, Boriani G. A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention. Eur Heart J. 2009;30:2758-2767.
16. Klein RC, Raitt MH, Wilkoff BL, Beckman KJ, Coromilas J, Wyse DG, Friedman PL, Martins JB, Epstein AE, Hallstrom AP, Ledingham RB, Belco KM, Greene HL; AVID Investigators. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol. 2003;14:940-948.
17. Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, Birgersdotter-Green UM, Wathen MS, Van Gelder IC, Heubner BM, Brown ML, Holloman KK; PREPARE Study Investigators. Strategic programming of detection and therapy parameters in implantable cardioverter- defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008;52:541-550.